Seagen (SGEN) – FDA
-
Seagen (SGEN) Reports ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% PFS at 12 months in Phase 2 Trial
-
Seagen (SGEN) Announces TUKYSA in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves PFS in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SGEN Stock Lookup